Russian COVID-19 Vaccine Sputnik V Meets Primary Safety Endpoint In Phase-2 Clinical Trials In India

Hyderabad: The Russian made COVID-19 vaccine Sputnik V has met the primary endpoint of safety in the phase-2 clinical trials in India and has been recommended to continue the clinical trial without any modifications, according to an official statement. Dr Reddy’s Laboratories Ltd said in a release that the Data and Safety Monitoring Board (DSMB) concluded that no safety concerns were identified and the study has met the primary endpoints of safety. “Dr Reddy’s Laboratories Ltd. announced today that the independent Data and Safety Monitoring Board (DSMB) has reviewed the safety data from the phase 2 clinical trial of the Sputnik V vaccine and recommended the phase 3 recruitment and continue the clinical trial without any modifications,” the release said.

Also Read: COVID-19 Vaccine Race: Where They Stand Currently

The phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India. The DSMB concluded that no safety concerns were identified and the study has met the primary endpoints of safety. Further, the safety data has been submitted to the Drugs Controller General of India (DCGI) for review and approval to continue phase 3 clinical trials, the release added.

G V Prasad, Co-chairman and Managing Director, Dr Reddy’s Laboratories said, “The Indian clinical trial being conducted by Dr. Reddy’s and RDIF is an adaptive design phase 2/3 trial. It is a bridging study to the larger global phase 3 study on 31,000 subjects. The phase 2 study in India showed a very good safety profile.”

Also Read: Amid Short Supplies, Vaccine Doses Can Be Six Weeks Apart, Says WHO

“We are working closely towards fast-tracking the launch of the Sputnik V vaccine in India,” Mr Prasad added. Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said,

The safety data from the phase 2 clinical trial from India is very positive, and confirms the safety profile of Sputnik V in the international markets. The Sputnik V consistently shows safety and high efficacy in international clinical trials as it is based on safe human adenoviral vector platform.

Also Read: COVID-19 Vaccination To Start In India On January 16; 3 Crore Healthcare, Frontline Workers To Get Shots First

In September 2020, Dr Reddy’s and Russian Direct Investment Fund (RDIF) entered into a partnership to conduct the clinical trials of the Sputnik V vaccine and the rights for distribution in India, the release said. As per the release, Sputnik V currently ranks among top 10 candidate vaccines approaching the end of clinical trials and the start of mass production on the World Health Organization’s (WHO) list.

The vaccine’s efficacy is confirmed at 91.4 per cent based on data analysis of the final control point of clinical trials in Russia, the release said. Currently, the vaccine’s clinical trials are underway in the UAE, Egypt, Venezuela and Belarus while it has been registered in Algeria, Argentina, Belarus, Bolivia and Serbia for inoculation.

Also Read: As India Gears Up To Kick-starts COVID-19 Vaccination Drive From January 16, Dr Randeep Guleria Explains When Will The Common Man Get The Vaccine

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (Water, Sanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollution, waste management, plastic ban, manual scavenging and sanitation workers and menstrual hygiene.